Form 425 HISTOGENICS CORP Filed by: HISTOGENICS CORP
Filed by Histogenics Corporation pursuant to
Rule 425 under the Securities Act of 1933
and deemed filed pursuant to Rule 14a-6
under the Securities Exchange Act of 1934
Subject Company: Histogenics Corporation (SEC File No. 001-36751)
Commission File No. for the Related Registration Statement: 333-232147
August 22, 2019
Dear Stockholder:
According to our latest records, we have not yet received your proxy for the important Special Meeting of Histogenics Corporation stockholders taking place on September 12, 2019 in connection with the proposed merger with Ocugen, Inc. Your Board of Directors unanimously recommends that stockholders vote FOR the merger and related proposals on the agenda.
THE MERGER CANNOT BE CONSUMMATED WITHOUT THE APPROVAL OF PROPOSAL NOS. 1 AND 2. Therefore, your vote is important, no matter how many or how few shares you may own.
Please help your company avoid the expense of further solicitation by voting TODAY by telephone, via the Internet, or by signing, dating and returning the enclosed proxy card in the postage-paid envelope provided.
Very truly yours,
Adam Gridley
President
Histogenics Corporation
REMEMBER:
You can vote your shares via the Internet.
Please follow the easy instructions on the enclosed proxy card.
If you have any questions, or need assistance in voting
your shares, please call our proxy solicitor:
INNISFREE M&A INCORPORATED
TOLL-FREE, at 1-888-750-5834.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- VILNIAUS BALDAI AB interim condensed consolidated report and consolidated financial statements for the six months of FY 2024
- TotalEnergies Celebrates its 100th Anniversary and Launches the Operation "100 for 100"
- Jimmy's Jazz & Blues Club Features 5x-GRAMMY® Award Nominated Jazz Pianist & Composer CHRISTIAN SANDS, a Steinway Artist, on Wednesday April 24 at 7:30 P.M.
Create E-mail Alert Related Categories
SEC FilingsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!